Lexicon Genetics and Takeda establish collaboration to develop new drugs for high blood pressure.(Lexicon Genetics Inc.)(Takeda Pharmaceuticals)

BIOTECH Patent News, July, 2004

Lexicon Genetics, Inc. (The Woodlands, TX) and Takeda Pharmaceutical Company Limited (Osaka, Japan) announced the formation of a collaboration to develop new drugs for the treatment of high blood pressure. The alliance is designed to accelerate the development and commercialization of new drugs directed against promising hypertension targets discovered in Lexicon's Genome5000 program.

In the collaboration, Takeda will have exclusive access to all drug targets from Lexicon's Genome5000 program that control blood pressure. In this program, Lexicon is using its proprietary gene knockout technology to rapidly discover the functions of 5,000 of the most pharmaceutically important genes in the human genome. Takeda will be responsible for the screening, medicinal...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.